OxyContin maker Purdue has reportedly been mulling a bankruptcy filling, just as the first of around 2,000 lawsuits against it prepares to go to trial.
The Trump administration’s proposal to lower drug prices focuses on discounts. A health policy scholar argues that the US could learn from Europe’s system of measuring drug value and effectiveness.
Clinical guidelines have a big impact on the care you receive and the drugs you’re prescribed. But one in five doctors who write these guidelines have undisclosed ties to drug companies.
A new book, ‘The Thalidomide Catastrophe,’ raises new questions about the conduct of corporations involved. It is the duty of governments to find out the answers.
Small-batch brewers are starting to tinker with biologic drugs to meet their own medical needs. A side effect of their success would be a disruption to how big pharma makes and distributes drugs.
In the run up to the Global Hepatitis Summit 2018, new guidelines for the management of hepatitis C should come under scrutiny – for financial conflict of interest and quality of evidence.
Pharmaceutical companies focus on small molecules they’ve devised – and can easily patent. But nature’s already come up with many antibacterial compounds that drug designers could use to make medicines.
Researchers use an algorithm designed to help robots move to figure out what’s possible when designing new molecules in a promising class of pharmaceuticals.